Singulair lawsuits are on the rise — here’s why

Montelukast, which is prescribed to treat asthma and allergies, has been making headlines as more people claim that the drug can have dangerous side effects on their mental health. These side effects can also be severe for children.

Singulair mental health symptoms

A March 2020 U.S. Food and Drug Administration (FDA) announcement that it would add a black boxed warning warning label to the drug — the FDA’s strongest warning label — has led to an increase in Singulair litigations. This label will warn patients of severe neuropsychiatric injuries, including depression and anxiety, as well as suicidal thoughts and behaviors.

 

After reviewing all medical literature regarding Singulair, the FDA decided to update the label. A panel of outside experts was convened to discuss the matter. The FDA also recommended that doctors only prescribe Singulair to patients with hay fever if other allergy medications have failed.

 

Singulair Lawsuits Allege Severe Psychiatric Injuries

The FDA approved Singulair in 1998 for the treatment and prevention of asthma attacks in children and adults. In 2018, 9.3 million prescriptions were filled for Singulair and its generics by patients. The FDA data shows that approximately 2.3 million prescriptions were written for children younger than 17 years.

 

Despite its popularity, the FDA investigated problems with Singulair in 2008, when it first looked into “a possible association between Singulair use and behavioral/mood change, including suicidality (suicidal thoughts and behaviors) and suicide”.

 

The FDA has announced that it will include additional information on neuropsychiatric side effects in its drug warning label following an investigation conducted in 2008.

 

Singulair may have neuropsychiatric side effects

Other than increased reports of depression and anxiety, as well as suicidal thoughtstion, there have been other injuries reported.

 

Agitation, aggression, and hostility

Attention problems

Vivid dreams or bad dreams

Confusion or disorientation

Hallucinations

Insomnia

Memory problems

Obsessive-compulsive symptoms

Stuttering

Tics and tremors

Uncontrolled muscle movements

Since August 2020, at most 14 Singulair lawsuits were filed.

 

Receive assistance in filing a single-level lawsuit

According to Healthline a report shows that the FDA’s decision not to include its most prominent boxed warning on Singulair (and generics) was a move many health advocates and organisations have been advocating for, with the Allergy and Asthma Network (AAN), being the chief.

 

Singulair lawsuits are on the rise — here’s why

Montelukast, which is prescribed to treat asthma and allergies, has been making headlines as more people claim that the drug can have dangerous side effects on their mental health. These side effects can also be severe for children.

 

A March 2020 U.S. Food and Drug Administration (FDA) announcement that it would add a black boxed warning warning label to the drug — the FDA’s strongest warning label — has led to an increase in Singulair litigations. This label will warn patients of severe neuropsychiatric injuries, including depression and anxiety, as well as suicidal thoughts and behaviors.

 

After reviewing all medical literature regarding Singulair, the FDA decided to update the label. A panel of outside experts was convened to discuss the matter. The FDA also recommended that doctors only prescribe Singulair to patients with hay fever if other allergy medications have failed.

 

Singulair Lawsuits Allege Severe Psychiatric Injuries

The FDA approved Singulair in 1998 for the treatment and prevention of asthma attacks in children and adults. In 2018, 9.3 million prescriptions were filled for Singulair and its generics by patients. The FDA data shows that approximately 2.3 million prescriptions were written for children younger than 17 years.

 

Despite its popularity, the FDA investigated problems with Singulair in 2008, when it first looked into “a possible association between Singulair use and behavioral/mood change, including suicidality (suicidal thoughts and behaviors) and suicide”.

 

The FDA has announced that it will include additional information on neuropsychiatric side effects in its drug warning label following an investigation conducted in 2008.

 

Singulair may have neuropsychiatric side effects

Other than increased reports of depression and anxiety, as well as suicidal thoughtstion, there have been other injuries reported.

 

Agitation, aggression, and hostility

Attention problems

Vivid dreams or bad dreams

Confusion or disorientation

Hallucinations

Insomnia

Memory problems

Obsessive-compulsive symptoms

Stuttering

Tics and tremors

Uncontrolled muscle movements

Since August 2020, at most 14 Singulair lawsuits were filed.

 

Receive assistance in filing a single-level lawsuit

According to Healthline a report shows that the FDA’s decision not to include its most prominent boxed warning on Singulair (and generics) was a move many health advocates and organisations have been advocating for, with the Allergy and Asthma Network (AAN), being the chief.

 

 

You may also like

Leave a Reply

Your email address will not be published.